Citigroup Inc. Analysts Give Alkermes PLC (ALKS) a $62.00 Price Target

Alkermes PLC (NASDAQ:ALKS) received a $62.00 price target from equities research analysts at Citigroup Inc. in a note issued to investors on Thursday, October 26th. The brokerage presently has a “hold” rating on the stock. Citigroup Inc.’s price objective suggests a potential upside of 29.57% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. Mizuho set a $81.00 target price on Alkermes PLC and gave the stock a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. ValuEngine lowered Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the stock a “buy” rating in a research note on Friday, August 25th. Finally, Barclays PLC lowered Alkermes PLC from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $66.00 to $50.00 in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. Alkermes PLC presently has a consensus rating of “Hold” and a consensus price target of $63.55.

Shares of Alkermes PLC (NASDAQ:ALKS) traded down $0.20 on Thursday, reaching $47.85. The company had a trading volume of 1,285,300 shares, compared to its average volume of 831,124. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05. Alkermes PLC has a twelve month low of $46.80 and a twelve month high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. The business had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm’s quarterly revenue was up 20.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) EPS. research analysts expect that Alkermes PLC will post -0.59 EPS for the current year.

WARNING: “Citigroup Inc. Analysts Give Alkermes PLC (ALKS) a $62.00 Price Target” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/14/citigroup-inc-analysts-give-alkermes-plc-alks-a-62-00-price-target.html.

In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the transaction, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard F. Pops sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,498 shares of company stock valued at $5,018,010. Company insiders own 5.34% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank increased its position in Alkermes PLC by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares in the last quarter. Quantbot Technologies LP bought a new position in Alkermes PLC during the 3rd quarter valued at approximately $126,000. Daiwa SB Investments Ltd. bought a new position in Alkermes PLC during the 2nd quarter valued at approximately $166,000. Dynamic Technology Lab Private Ltd bought a new position in Alkermes PLC during the 3rd quarter valued at approximately $214,000. Finally, Trexquant Investment LP bought a new position in Alkermes PLC during the 3rd quarter valued at approximately $218,000. 98.11% of the stock is owned by institutional investors.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Analyst Recommendations for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply